Summit Therapeutics (SMMT) vs TG Therapeutics (TGTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
TG Therapeutics (TGTX) has outperformed Summit Therapeutics (SMMT) over the past year, gaining 98.2% versus a loss of 38.5%. Over five years, TGTX leads with a +164.1% price change compared with +92.8% for SMMT. TG Therapeutics is the larger company by market cap ($9.57 billion vs $7.96 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SMMT | TGTX |
|---|---|---|
| Share price | $9.95 | $63.34 |
| Market cap | $7.96B | $9.57B |
| 1-day change | -5.87% | -2.37% |
| YTD return | -43.11% | +112.48% |
| 1-year return | -38.54% | +98.25% |
| 5-year return | +92.83% | +164.14% |
| P/E ratio (TTM) | — | 94.54 |
| Forward P/E | — | 24.81 |
| EPS (TTM) | $-1.06 | $0.67 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $616.29M |
| Revenue growth (YoY) | — | +87.32% |
| Net income (latest FY) | $-1.08B | $447.18M |
| Gross margin | — | 83.66% |
| Operating margin | — | 20.01% |
| Net margin | — | 72.56% |
| 52-week high | $29.23 | $68.03 |
| 52-week low | $9.89 | $26.76 |
| Distance from 52-week high | -65.96% | -6.89% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +189.15% | +9.61% |
| Average volume | 6.68M | 1.86M |
| Shares outstanding | 799.76M | 151.15M |
| Employees | 265 | 399 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TGTX has outperformed SMMT by 136.8 percentage points over the past year.
About Summit Therapeutics
SMMT stock →Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC).
Health Care · Biotechnology: Pharmaceutical Preparations · 265 employees
About TG Therapeutics
TGTX stock →TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Health Care · Biotechnology: Pharmaceutical Preparations · 399 employees
SMMT vs TGTX FAQ
Which is bigger, Summit Therapeutics or TG Therapeutics?
TG Therapeutics (TGTX) is larger, with a market capitalization of $9.57B compared with $7.96B for Summit Therapeutics (SMMT).
Which stock has performed better over the past year, SMMT or TGTX?
TGTX returned +98.25% over the past 12 months, compared with -38.54% for SMMT (price return, excluding dividends). Past performance does not predict future results.
Are Summit Therapeutics and TG Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.